A new toy called the Nail Box that can be set to work on a single nail can be a lifesaver for people with cancer, a new study finds.
In an observational study, researchers at the University of Waterloo looked at a series of trials to determine how effective the Nixle system is at preventing cancer in people who have received treatment for cancer, and how effective it was at helping people who had not received treatment to live longer.
The researchers found that the Nile Box, which cost about $20 and was first introduced in 2010, had a 97 per cent success rate when it was used as part of a cancer-treatment protocol.
“Nail Box is a real life experience that you can have in your pocket that is very beneficial to those who have had a positive response to treatment,” said lead researcher and assistant professor of surgery and radiology Dr. Susan O’Brien.
“We are talking about a real time saving device.”
The device has three different levels of stimulation, and can be programmed to respond to a single, single-digit number or to a series that can respond to more than one number.
A number of studies have shown that the number of days cancer patients live is associated with the rate of recurrence, and in this study, the researchers found the number at the top of the Nule Box response scale was associated with a lower rate of relapse.
The number at this level is not necessarily a positive number, but it is a high number that is correlated with the patient’s chance of recurrences.
After a patient receives treatment, the Nille Box can be re-programmed to respond by sending out a signal to an alarm clock that tells the device if it is time to move.
When patients are in the control room, the device can also send out a single alarm if it detects that the patient is awake and is in the treatment room.
Once the patient has been on the Niles for 30 days, the team found the device was able to stop the recurrence rate of the patient.
Another study published last year in the journal The Lancet found that patients who received a low dose of the drug mesothelioma-suppressing medication, Zidovudine, had more than a 90 per cent survival rate compared to patients who did not receive it.
The study was conducted by researchers at Memorial Sloan Kettering Cancer Center in New York City.
The researchers also found that if patients received a daily dose of Zidogine, the patient had a 90-per-cent survival rate.
This is the first study to show that using the NilaBox in conjunction with cancer treatment can have a dramatic effect on patients’ lives.
“This is something that can save lives,” said co-author and clinical professor of radiology Professor David R. Anderson, also a researcher at Memorial.
“It’s very important to think about whether you’re going to have an effect on your cancer recurrence rates.
It can change how quickly you live.”